新型睡眠药物地达西尼的研究现状

Research Status of new sedative-hypnotic drug Dimdazenil

失眠是最常见的睡眠问题,在普通人群中的患病率高,并且逐步呈年轻化趋势。地达西尼是一种新型的睡眠药物,属于部分GABAA-R部分激动剂,通过选择性作用于GABAA-R的α1亚基,起到镇静催眠的作用,同时减轻完全激动剂所致的不良反应。此外,地达西尼消除半衰期短,耐受性和残留不良反应的风险也有所降低。地达西尼的Ⅰ~Ⅲ期临床试验已完成,均显示其具有较好的有效性和安全性。本文主要阐述了地达西尼治疗失眠的药理机制和三期临床研究。

Insomnia is the most common sleep problem,with a high prevalence among the general population and a gradual trend towards younger age groups.Dimdazenil is a novel sleep medication that belongs to the category of partial GABAA-R agonists.By selectively acting on the alpha 1 subunit of GABAA-R,it exerts sedative and hypnotic effects while reducing adverse reactions caused by complete agonists.In addition,the elimination half-life of Dimdazenil is 3-4 hours,and the risk of tolerance and residual adverse reactions is also reduced.As of now,the PhaseⅠ-Ⅲclinical trials of this drug have been completed,all of which have shown its good efficacy and safety,and have great prospects in the treatment of insomnia.This article mainly elaborates on the pharmacological mechanism and three-stage clinical research of Dimdazenil in the treatment of insomnia.